Small bowel adenocarcinoma (SBA) is a rare and increasingly recognised malignancy, accounting for only 3.4% of all gastrointestinal cancers. It often presents with non-specific or late-stage symptoms, resulting in delayed diagnosis and poor prognosis. For advanced disease, treatment recommendations rely primarily on small phase II trials and retrospective series with no established standard therapy. Moreover, although SBA commonly harbours KRAS mutations (43%), CDKN2A (p16) loss, and HER2/ERBB2 mutations (12%), no targeted biological agents have demonstrated clinical efficacy against this disease. Our systematic review was conducted to comprehensively evaluate the available evidence on systemic therapies for patients with advanced or metastatic SBA, with particular focus on treatment efficacy, safety profiles, and the potential influence of molecular biomarkers.
Treatment options for advanced small bowel adenocarcinoma: a systematic review
Ghidini M.;
2025-01-01
Abstract
Small bowel adenocarcinoma (SBA) is a rare and increasingly recognised malignancy, accounting for only 3.4% of all gastrointestinal cancers. It often presents with non-specific or late-stage symptoms, resulting in delayed diagnosis and poor prognosis. For advanced disease, treatment recommendations rely primarily on small phase II trials and retrospective series with no established standard therapy. Moreover, although SBA commonly harbours KRAS mutations (43%), CDKN2A (p16) loss, and HER2/ERBB2 mutations (12%), no targeted biological agents have demonstrated clinical efficacy against this disease. Our systematic review was conducted to comprehensively evaluate the available evidence on systemic therapies for patients with advanced or metastatic SBA, with particular focus on treatment efficacy, safety profiles, and the potential influence of molecular biomarkers.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
